# ulcerative colitis (UC) - gpt-5.6-luna

- Benchmark system: E2seq + Agent RAG
- Repeat: 3
- Task type: DISEASE-STATE
- Tissue / sample source: colonic mucosal tissue
- Comparison or endpoint: ulcerative colitis versus healthy control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: 478acec7ab00f0e9bda085b6ecab7aa16a2bc8aa5cde3f2ba8fb71b2af94f79a
- Response HTTP status: 200
- Prompt tokens: 48157
- Completion tokens: 18060
- Reasoning tokens: 0
- Total tokens: 66217
- API requests reported: 3
- Elapsed seconds: 161.487
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1095.213
- Question handoff seconds: 1109.559
- Final benchmark system: E2seq; file rank 2/5; original repeat 3; model vendor: OpenAI

---
## Data-quality and evidence status

The statistical pattern is extremely strong: all **100 unique genes** have **FDR ≤ 0.01**, with **40 upregulated** and **60 downregulated** genes. However, the input contains **175 retained rows and 43 duplicated genes/probes**, including grouped probe/gene labels such as `CYP2B7P|CYP2B6`, `NAT8B|NAT8`, and `UBD|GABBR1`. This is not necessarily invalid, but it requires checking probe annotation, gene collapsing, normalization, sample size, batch structure, and whether the p-values are inflated by technical or compositional effects.

The interpretation below therefore separates:

- **Direct evidence:** the supplied UC-versus-control log2FC, P value, and FDR.
- **External contextual evidence:** GO, Reactome, KEGG, STRING, regulatory records, tissue/disease annotations, and literature.
- **Replication:** **external statistical validation was not performed**; no independent-cohort effect sizes, P values, or FDR values were supplied.

## 1. Overall biological interpretation

The colonic mucosa shows a coherent disease-associated transition from a differentiated absorptive and transport-oriented epithelial state toward an inflamed, stressed, remodeling mucosa.

The dominant upregulated features include:

- epithelial oxidative and antimicrobial responses: **DUOX2, DUOXA2, LCN2, PI3**
- neutrophil-associated and inflammatory chemokine signals: **S100A8, CXCL1, CXCL2, CXCL3, PLA2G2A**
- tissue injury and extracellular-matrix remodeling: **MMP3, TNC, TGM2, TIMP1, CHI3L1, PDPN**
- immune and regulatory activation: **CTLA4, DAPP1, SOCS3, IRAK3, IFI16**
- epithelial injury, repair, or altered differentiation: **REG4, TRIM29, SERPINB5, CDH3, PRRX1**

In parallel, several genes associated with epithelial fluid transport, nutrient handling, xenobiotic or bile-related transport, and differentiated metabolic activity are strongly downregulated, including **AQP8, AQP7, SLC51A, SLC38A4, SLC16A1, HMGCS2, G6PC, ABCG2, ABCB11, MEP1B, and DEFB1**.

Taken together, this resembles an inflamed and structurally remodeled UC mucosa with impaired or altered epithelial transport and metabolic specialization. The pattern is biologically plausible for active mucosal disease, but it cannot distinguish intrinsic epithelial reprogramming from changes in epithelial, stromal, myeloid, neutrophil, and lymphoid cell proportions.

## 2. Core biological programs

### Program 1 — Innate inflammatory, antimicrobial, and oxidative mucosal response

**Direction:** Upregulated.

**Major supporting genes:**  
`DUOX2` (**log2FC 4.666, FDR 4.448e-26**), `DUOXA2` (**2.892, 1.117e-10**), `S100A8` (**3.799, 4.434e-11**), `LCN2` (**2.668, 1.373e-21**), `CXCL1` (**3.456, 1.152e-15**), `CXCL2` (**2.799, 1.728e-11**), `CXCL3` (**2.330, 2.506e-11**), `PLA2G2A` (**1.535, 1.357e-11**), `PI3` (**2.208, 3.968e-19**), and `IFI16` (**1.386, 2.595e-11**).

**Relevant pathways:**  
- KEGG **IL-17 signaling pathway**  
- GO **defense response**, **response to bacterium**, **chemotaxis**, and **innate immune response in mucosa**
- Reactome **defensins**, where applicable to `DEFB1`

**Interpretation:**  
The coordinated induction of epithelial oxidant generation (`DUOX2/DUOXA2`), antimicrobial or neutrophil-associated genes (`LCN2`, `PI3`), alarmin-like myeloid signals (`S100A8`), and several chemokines supports active inflammatory recruitment in the mucosa. The three chemokines form a particularly coherent inflammatory axis rather than an isolated single-gene result. The supplied network records place `CXCL1`, `CXCL2`, and `CXCL3` in a common **CXCR2-associated network**, but this indicates pathway or ligand-receptor network association, not necessarily direct physical interaction among the chemokines.

**Evidence strength:** Strong direct transcriptomic evidence and strong biological coherence; supported by pathway annotations and network records.

**Limitations:** The signal may reflect increased neutrophil or inflammatory-cell abundance rather than increased transcription within epithelial cells. The available KEGG/GO output is a retrieved annotation summary, not a newly calculated enrichment P value. The IL-17 assignment is therefore contextual rather than statistically validated in this dataset.

---

### Program 2 — Loss or remodeling of epithelial transport, barrier, and absorptive metabolism

**Direction:** Predominantly downregulated.

**Major supporting genes:**  
`AQP8` (**log2FC -4.417, FDR 1.603e-13**), `AQP7` (**-2.322, 4.037e-20**), `SLC51A` (**-3.711, 1.537e-20**), `SLC38A4` (**-3.067, 4.699e-37**), `SLC16A1` (**-2.375, 5.825e-21**), `HMGCS2` (**-3.445, 1.100e-16**), `G6PC` (**-1.523, 1.921e-17**), `ABCG2` (**-2.919, 1.112e-10**), `ABCB11` (**-1.148, 8.911e-11**), `MEP1B` (**-2.991, 1.108e-22**), and `DEFB1` (**-2.305, 1.251e-10**).

**Relevant pathways:**  
- GO **fluid transport**, **water transport**, and **carboxylic acid transport**
- Reactome **passive transport by aquaporins**
- KEGG **bile secretion**
- Reactome **detoxification of reactive oxygen species**, particularly in relation to `AQP8`

**Interpretation:**  
The simultaneous reduction of aquaporin genes, solute transporters, bile-related transport genes, and epithelial metabolic genes indicates loss or remodeling of a mature absorptive epithelial program. The magnitude of `AQP8` downregulation is notable, but the interpretation is strengthened by the concordant direction of multiple transport and metabolic genes. Reduced `DEFB1` suggests that not all mucosal defense mechanisms are induced: inducible oxidative and neutrophil-associated defenses are increased, whereas this constitutive epithelial antimicrobial component is decreased.

**Evidence strength:** Strong direct dataset support for a transport/metabolic state change; supported by Reactome and GO annotations.

**Limitations:** This program may primarily reflect loss of mature colonocyte or epithelial subtypes from inflamed tissue. It does not establish a cell-intrinsic defect in transport. The presence of `ABCB11` and bile-secretion annotations should not be interpreted as evidence of a primary hepatobiliary disease mechanism in the colon.

---

### Program 3 — Tissue injury, extracellular-matrix remodeling, and reparative activation

**Direction:** Upregulated.

**Major supporting genes:**  
`MMP3` (**log2FC 4.642, FDR 5.399e-14**), `TNC` (**2.579, 2.506e-11**), `TGM2` (**1.907, 1.562e-10**), `TIMP1` (**1.969, 1.810e-17**), `CHI3L1` (**4.590, 3.201e-11**), `PDPN` (**2.539, 1.747e-10**), `PRRX1` (**2.907, 4.349e-16**), `SERPINB5` (**3.294, 2.575e-17**), and `CDH3` (**2.293, 2.595e-11**).

**Relevant pathways/terms:**  
- GO extracellular region and extracellular matrix-related terms
- Reactome/GO annotations for extracellular matrix and tissue remodeling
- The supplied network records connect `FREM2`, `TGM2`, and `TNC` through an **ITGB1-associated network**

**Interpretation:**  
The combination of matrix metalloprotease activity (`MMP3`), matricellular signaling (`TNC`), transglutaminase activity (`TGM2`), matrix regulation (`TIMP1`), and stromal or repair-associated markers (`PDPN`, `PRRX1`, `CHI3L1`) is consistent with tissue injury and wound-repair remodeling. The simultaneous elevation of `MMP3` and `TIMP1` may represent active matrix turnover with compensatory inhibition rather than simple matrix degradation.

**Evidence strength:** Strong direct multi-gene evidence, with pathway and network plausibility.

**Limitations:** These genes may originate from fibroblasts, stromal cells, epithelial repair states, macrophages, or mixed tissue compartments. The `ITGB1` relationship is network-level contextual evidence; it does not demonstrate direct physical binding among `FREM2`, `TGM2`, and `TNC`.

---

### Program 4 — Immune-cell recruitment and adaptive immune-regulatory activity

**Direction:** Upregulated.

**Major supporting genes:**  
`CTLA4` (**log2FC 2.616, FDR 1.112e-10**), `DAPP1` (**2.204, 2.850e-14**), the immunoglobulin-containing feature `LOC100290146|IGHV4-31|IGHM|IGHG1|IGH` (**1.891, 3.725e-22**), `CD55` (**2.038, 1.117e-10**), `IRAK3` (**1.782, 2.103e-11**), and `SOCS3` (**2.786, 8.131e-12**), considered alongside the chemokines in Program 1.

**Relevant pathways/terms:**  
- immune-response and regulatory signaling annotations
- KEGG IL-17 signaling context
- protein/regulatory network records for `DAPP1`, `IRAK3`, `SOCS3`, and `CTLA4`

**Interpretation:**  
The immunoglobulin feature suggests increased B-cell or plasma-cell-associated transcript contribution, while `CTLA4` is compatible with activated or regulatory T-cell populations. `DAPP1` supports hematopoietic signaling, and `SOCS3` and `IRAK3` are consistent with feedback regulation of inflammatory signaling. This indicates a mixed mucosal immune response rather than a purely neutrophilic process.

**Evidence strength:** Strong direct expression evidence for immune-associated transcripts; pathway and disease annotations provide plausibility.

**Limitations:** `CTLA4` and the immunoglobulin feature are especially sensitive to cell composition. These data do not establish whether adaptive immune activation is pathogenic, compensatory, or treatment-related. The composite immunoglobulin probe should be re-annotated before gene-specific biological interpretation.

---

### Program 5 — Epithelial injury-associated differentiation and compensatory regeneration

**Direction:** Upregulated for injury/repair markers, with loss of selected differentiated epithelial genes.

**Major supporting genes:**  
`REG4` (**log2FC 2.051, FDR 5.123e-17**), `TRIM29` (**2.832, 4.915e-19**), `S100P` (**1.775, 1.218e-21**), `CDH3` (**2.293, 2.595e-11**), `SERPINB5` (**3.294, 2.575e-17**), `SLC6A14` (**4.849, 8.073e-39**), `VNN1` (**3.199, 1.540e-15**), and downregulated epithelial-state genes such as `MEP1B`, `AQP8`, `HMGCS2`, and `B4GALNT2`.

**Relevant pathways/terms:**  
No single standardized pathway is sufficiently specific from the supplied annotation summary. The most appropriate interpretation is an epithelial injury/regeneration and differentiation-state program, rather than a formally demonstrated pathway enrichment.

**Interpretation:**  
The contrast between induction of `REG4`, `TRIM29`, `S100P`, `CDH3`, and `SERPINB5` and suppression of mature transport/metabolic genes suggests epithelial-state remodeling. It may represent regenerative or wound-associated epithelium replacing mature absorptive cells. `SLC6A14` is strongly induced, but it should not be elevated as a disease mechanism by itself; its interpretation depends on cell-type and epithelial-state localization.

**Evidence strength:** Supported hypothesis based on a coordinated expression pattern.

**Limitations:** This program is less specific than the inflammatory and transport programs. It could reflect epithelial subtype redistribution, repair, medication effects, or disease severity. Formal pathway enrichment for this exact biological concept was not supplied.

## 3. Key genes and interaction modules

1. **DUOX2–DUOXA2 oxidative epithelial-defense module**  
   - `DUOX2`: up, **log2FC 4.666**, **FDR 4.448e-26**.  
   - `DUOXA2`: up, **2.892**, **1.117e-10**.  
   - These genes are functionally linked in epithelial oxidant generation. This is best described as **pathway/functional co-membership**, not a claim of direct physical interaction from the supplied records.

2. **CXCL1–CXCL2–CXCL3 chemokine module**  
   - All are upregulated: `CXCL1` **3.456**, `CXCL2` **2.799**, `CXCL3` **2.330** log2FC.  
   - STRING/network records connect these ligands with **CXCR2**, and OmniPath-related records associate `CXCL1/CXCL2` with `ADRA2A`. The most defensible relationship is **ligand–receptor network association and pathway co-membership**, not direct physical interaction among CXCL1, CXCL2, and CXCL3.

3. **S100A8–LCN2–PI3 inflammatory/antimicrobial module**  
   - `S100A8`, `LCN2`, and `PI3` are all upregulated with FDR values from **4.434e-11 to 3.968e-19**.  
   - Their relationship is **co-expression and functional co-membership** in inflammatory and antimicrobial mucosal biology. The data do not establish that one regulates another.

4. **AQP7–AQP8 epithelial water-transport module**  
   - `AQP7`: down, **log2FC -2.322**, **FDR 4.037e-20**.  
   - `AQP8`: down, **-4.417**, **1.603e-13**.  
   - Reactome and QuickGO support aquaporin-mediated water transport. This is **pathway co-membership**; a direct physical interaction is not demonstrated.

5. **SLC51A–ABCG2–ABCB11 epithelial transport module**  
   - `SLC51A`, `ABCG2`, and `ABCB11` are all downregulated.  
   - Their relationship is **transport-pathway co-membership** and possibly shared epithelial-state dependence, not direct interaction. The bile-secretion annotation is contextual and not evidence of a primary bile-acid disorder.

6. **MMP3–TNC–TGM2–TIMP1 remodeling module**  
   - All four are upregulated; `MMP3` and `TNC` show particularly large effects.  
   - The proposed relationship is **extracellular-matrix pathway co-membership and indirect tissue-remodeling association**. The supplied network places `FREM2`, `TGM2`, and `TNC` in an ITGB1-associated network, but does not establish a direct physical interaction for every pair.

7. **PRRX1–PDPN–CHI3L1 stromal/repair-associated module**  
   - All are upregulated: `PRRX1` **2.907**, `PDPN` **2.539**, `CHI3L1` **4.590** log2FC.  
   - The relationship is **co-expression and indirect tissue-repair/stromal association**. Cell-type localization is required before assigning this module to fibroblasts, epithelial cells, or macrophages.

8. **CTLA4–DAPP1–SOCS3–IRAK3 immune-regulatory module**  
   - All are upregulated, with `CTLA4` **2.616**, `DAPP1` **2.204**, `SOCS3` **2.786**, and `IRAK3` **1.782** log2FC.  
   - The relationship is **regulatory/pathway co-membership** in immune activation and feedback control. Direct physical interaction among these proteins is not established by the supplied evidence.

9. **BRINP3 as a disease-relevant downregulated candidate**  
   - `BRINP3` is downregulated, **log2FC -2.133**, **FDR 6.953e-12**.  
   - A UC-focused publication specifically discusses underexpression of `BRINP3` in UC mucosa (PubMed **PMID: 25171508**). This is external disease-association and literature support, but not independent statistical replication of the present cohort.

10. **G6PC metabolic interaction context**  
    - `G6PC` is downregulated, **log2FC -1.523**, **FDR 1.921e-17**.  
    - STRING records report interactions with `GCK`, `SLC37A4`, `HK2`, `HK3`, and `HKDC1`. These are **database-supported protein/network associations**, not interactions demonstrated in this UC dataset. They support prioritizing epithelial glucose-handling follow-up, not a causal conclusion.

## 4. Validation priorities

### 1. Spatial and single-cell localization of inflammatory versus epithelial signals  
**Class:** Confounding or composition check

**Why prioritize:** The strongest signals could arise from both true cell-state changes and altered proportions of epithelial, neutrophil, macrophage, stromal, B-cell, and T-cell populations.

**Current evidence:** Strong induction of `S100A8`, `CXCL1/2/3`, `LCN2`, `CTLA4`, and immunoglobulin transcripts, together with loss of epithelial transport genes.

**External evidence:** Tissue-expression and disease annotations support these genes as biologically plausible, but they do not resolve their cellular origin. The literature record for `BRINP3` specifically concerns mucosal expression, but no independent cohort statistic was supplied.

**Next step:** Perform single-cell or spatial transcriptomics, or at minimum immunohistochemistry/RNAscope for `DUOX2`, `S100A8`, `LCN2`, `AQP8`, `CTLA4`, `PDPN`, and `MMP3`, together with epithelial and immune markers.

**Conclusion status:** **Supported hypothesis** for mixed inflammatory and epithelial remodeling; cell-specific causality remains exploratory.

---

### 2. Validate the epithelial transport and metabolic defect  
**Class:** Mechanistic hypothesis

**Why prioritize:** The coordinated downregulation of `AQP8`, `AQP7`, `SLC51A`, `SLC38A4`, `SLC16A1`, `HMGCS2`, `G6PC`, `ABCG2`, and `MEP1B` is one of the most coherent opposing-direction patterns in the dataset.

**Current evidence:** Strong and statistically consistent transcriptomic downregulation, including `AQP8` **log2FC -4.417** and `SLC38A4` **-3.067**.

**External evidence:** Reactome and GO support aquaporin-mediated water transport and epithelial transport functions. These annotations are mechanistic context, not independent validation.

**Next step:** Measure protein abundance, epithelial localization, organoid transport assays, transepithelial electrical resistance, water flux, and short-chain fatty-acid or bile-acid transport in UC and control tissue.

**Conclusion status:** **Supported hypothesis**, not an established cell-intrinsic defect.

---

### 3. Test the CXCL1/CXCL2/CXCL3–CXCR2 inflammatory axis  
**Class:** Mechanistic hypothesis

**Why prioritize:** Three related chemokines are independently upregulated, suggesting coordinated recruitment signaling rather than a single-marker effect.

**Current evidence:** `CXCL1`, `CXCL2`, and `CXCL3` are all significantly upregulated, with FDR values between **1.152e-15 and 1.728e-11**.

**External evidence:** STRING records provide CXCR2-associated network context, and pathway annotations support chemotaxis. These records do not establish that the axis is causal in this cohort.

**Next step:** Confirm protein concentrations in tissue or mucosal lavage, localize ligand and receptor expression, and test neutrophil migration or epithelial–myeloid co-culture responses with pathway inhibition.

**Conclusion status:** **Supported hypothesis**; therapeutic efficacy is unproven.

---

### 4. Characterize the MMP3–TNC–TGM2 matrix-remodeling response  
**Class:** Interaction / network hypothesis

**Why prioritize:** `MMP3`, `TNC`, `TGM2`, `TIMP1`, `PDPN`, and `CHI3L1` collectively indicate active tissue remodeling and may distinguish repair from progressive barrier injury.

**Current evidence:** Strong upregulation, including `MMP3` **log2FC 4.642**, `TNC` **2.579**, and `CHI3L1` **4.590**.

**External evidence:** GO/QuickGO supports extracellular-matrix and enzymatic functions; network records associate `FREM2`, `TGM2`, and `TNC` with an ITGB1-related network. This is not evidence of direct physical interaction in UC tissue.

**Next step:** Use spatial proteomics or immunostaining, matrix-degradation assays, and co-culture or organoid–fibroblast systems to test whether these genes track wound repair, fibrosis-like remodeling, or active mucosal damage.

**Conclusion status:** **Supported hypothesis** for remodeling; the specific network mechanism is exploratory.

---

### 5. Evaluate a compact molecular panel as a disease-state biomarker  
**Class:** Biomarker

**Why prioritize:** A panel combining inflammatory, epithelial, and remodeling dimensions is more likely to represent UC mucosal state than any single gene. Candidate components include `S100A8`, `LCN2`, `DUOX2`, `CXCL1`, `MMP3`, `AQP8`, and `HMGCS2`.

**Current evidence:** All selected candidates have FDR values below **0.01** in the supplied comparison, with both large positive and negative effects.

**External evidence:** UC-focused literature exists for transcriptomic biomarker discovery, including PubMed **PMID: 41029776**, and literature specifically links `BRINP3` underexpression with UC mucosa (**PMID: 25171508**). However, these records do not provide an independent-cohort statistic for this exact panel.

**Next step:** Predefine the panel, test it in an independent UC/control cohort, and evaluate associations with endoscopic activity, histologic inflammation, treatment exposure, and remission. Use an independent model rather than selecting markers by the current FDR alone.

**Conclusion status:** **Exploratory hypothesis**; external statistical validation was not performed.

## 5. Limitations and alternative explanations

1. **Cell composition and tissue architecture**  
   Increased neutrophils, myeloid cells, lymphocytes, or stromal cells can produce apparent upregulation of inflammatory and remodeling genes, while loss of mature epithelial cells can produce apparent downregulation of transport genes. This should be tested with single-cell deconvolution, histology, spatial profiling, and cell-type marker normalization.

2. **Disease activity and treatment exposure**  
   Active inflammation, corticosteroids, biologics, antibiotics, and other treatments can alter chemokines, antimicrobial genes, epithelial differentiation, and metabolic pathways. Clinical metadata and stratified analysis are needed.

3. **Probe and annotation structure**  
   The 43 duplicated genes/probes and composite identifiers may reflect multiple probes, overlapping transcripts, pseudogenes, or ambiguous mappings. Probe-level inspection and updated annotation are required before using individual genes as biomarkers.

4. **Technical or statistical inflation**  
   The fact that all 100 unique genes are highly significant, combined with very small P values and large effects, warrants inspection of sample size, replicate structure, normalization, batch correction, hidden covariates, and independent validation. The results should not be treated as robustly replicated merely because the FDR values are small.

5. **Association does not establish causality**  
   The transcriptome describes a UC-associated mucosal state. It does not show whether inflammatory signaling causes epithelial transport loss, whether epithelial injury initiates inflammation, or whether both result from a third factor such as disease severity or treatment. Drug or clinical-trial records, where available, are therapeutic context only and do not establish efficacy for UC.

**Bottom line:** The most defensible interpretation is a UC mucosal state characterized by coordinated innate inflammation and chemotaxis, epithelial oxidative defense, loss or remodeling of transport and absorptive metabolism, and extracellular-matrix repair activity. These conclusions are strongly supported within the supplied dataset but remain unreplicated across independent cohorts and require cell-resolved, protein-level, and functional validation.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=20, external claims checked=0, external mismatches=0, status=passed.

Answer model API: OpenAI / gpt-5.6-luna

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 94/100 selected items (records returned); cbioportal 87/100 selected items (records returned); chembl 40/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 51/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 55/100 selected items (partially returned; some queries failed); europepmc 936 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 91/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 85/100 selected items (records returned); humanbase 87/100 selected items (records returned); intact 85/100 selected items (records returned); mygene 93/100 selected items (records returned); omnipath 45/100 selected items (records returned); opentargets 92/100 selected items (records returned); pubmed 750 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 87/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 88/100 selected items (records returned)
Local databases: gutmgene 8/100 selected items (records returned); hmdb 46/100 selected items (records returned); string 85/100 selected items (records returned); trrust 31/100 selected items (records returned)
